GAM
AKRO

Griffin Asset Management’s Akero Therapeutics AKRO Stock Holding History

Griffin Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,300
Closed -$25K – 236
2019
Q2 		$25K Buy
+1,300
New +$24.6K ﹤0.01% 410

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Griffin Asset Management's AKRO Position: Q3 2019 in Review

Griffin Asset Management sold out of Akero Therapeutics (AKRO) in Q3 2019, closing a stake of 1,300 shares — an estimated $25K sold.

Griffin Asset Management first reported a position in AKRO in Q2 2019 and held it in 1 quarter. The position peaked at $25K in Q2 2019. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Griffin Asset Management reported no remaining Akero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Griffin Asset Management sold 1,300 Akero Therapeutics shares in Q3 2019, an estimated $25K.
  • Griffin Asset Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 1 quarter.
  • Griffin Asset Management's Akero Therapeutics position peaked at $25K in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Griffin Asset Management's 13F filing for Q3 2019, filed 5 Nov 2019.